
VC firms back series-B extension for Omeicos
A consortium of VC firms and life sciences investors has backed a series-B funding round extension for Berlin-based biopharmaceutical company Omeicos Therapeutics.
US-based Remiges Ventures led the financing with support from Vesalius Biocapital II, SMS Group, VC Fond Technologie Berlin, High-Tech Gründerfonds (HTGF) and KfW Group.
HTGF backed the company from its second fund, which held a final close on €301.5m in January 2013.
The fresh capital will be used to expand the company's technology into new fields and pre-clinically test a range of compounds. Omeicos has simultaneously announced the establishment of a US subsidiary in Cambridge, Massachusetts.
Previous funding
In April 2015, Vesalius led a €6.2m series-A funding round for Omeicos. IBB Beteiligungsgesellschaft and KfW also took part. Life-sciences-focused asset management company Ascenion also provided Omeicos with a €550,000 subsidy from its Spinnovator grant programme, which is backed by the German Ministry of Education and Research.
In March 2017, Vesalius led an €8.3m series-B round for the company with participation from all previous investors as well as SMS Group, the Falck Revocable Trust and management. This funding was to be used to start phase-I clinical trials of one of the compounds on 100 volunteers.
Company
Headquartered in Berlin, Omeicos develops a molecule focusing on the prevention and treatment of cardiovascular diseases. Founded in 2013, the pre-revenue business span out from the Max Delbrueck Center for Molecular Medicine.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater